What types of diseases is Elafibranor mainly used for?

Elafibranor is a new oral drug that is a peroxisome proliferator-activated receptor (PPAR) α/δ dual agonist. It is mainly used to treat non-alcoholic steatohepatitis (NASH). NASH is an increasingly common chronic liver disease worldwide. It is usually closely related to metabolic syndrome, obesity, type 2 diabetes and hyperlipidemia. If left untreated, it may develop into liver fibrosis, cirrhosis and even liver cancer. Ilafibratenol regulates lipid metabolism, improves insulin sensitivity, and has anti-inflammatory and anti-fibrotic effects by activating the PPAR pathway, thereby slowing down disease progression.

Ilafibratenol is currently being studied mainly for the treatment of patients with NASH combined with liver fibrosis (F2-F3 stage). In multiple international clinical trials, data show that the drug can improve liver tissue inflammation and steatosis in patients without significant weight loss, and some patients have also observed reversal of fibrosis. Compared with traditional treatments based on lifestyle intervention, irafibratenol is expected to become one of the first targeted drugs for the treatment of NASH, and therefore has received widespread attention in the field of liver diseases around the world.

Although irafibratenol has not yet been officially launched in mainland China, it has entered late-stage clinical trials in many countries. In European and American countries, Genfit, the drug's R&D company, has cooperated with Ipsen to promote market application. According to the information disclosed so far, the drug is well tolerated, with common adverse reactions including mild gastrointestinal discomfort and changes in blood lipids, and the overall safety is relatively controllable. After it is launched in the future, it is expected to fill the long-term lack of specific drugs in the field of NASH.

To sum up, irafibratenol, as an innovative targeted drug, is mainly used in the treatment of patients with NASH combined with liver fibrosis. As the incidence of non-alcoholic liver disease continues to rise globally, the clinical value and market potential of this type of drug has become increasingly prominent. If it can be approved for marketing in more countries in the future and further included in the medical insurance system, it will significantly improve the treatment accessibility and quality of life of NASH patients.

Reference materials:https://www.drugs.com/donanemab.html